Navigation

  • Skip to Content
NTNU Home NTNU Home

ntnu.edu

  • Studies
    • Master's programmes in English
    • For exchange students
    • PhD opportunities
    • All programmes of study
    • Courses
    • Financing
    • Language requirements
    • Application process
    • Academic calendar
    • FAQ
  • Research and innovation
    • NTNU research
    • Research excellence
    • Strategic research areas
    • Innovation resources
    • PhD opportunities
  • Life and housing
    • Student in Trondheim
    • Student in Gjøvik
    • Student in Ålesund
    • For researchers
    • Life and housing
  • About NTNU
    • Contact us
    • Faculties and departments
    • Libraries
    • International researcher support
    • Vacancies
    • About NTNU
    • Maps
  1. Employees

Språkvelger

Norsk

Andrew Single

Download press photo
Download press photo
Foto:

Andrew Single

Researcher
Department of Clinical and Molecular Medicine

andrew.single@ntnu.no
Kunnskapssenteret Øya, Trondheim
ResearchGate Google Scholar ORCID ID
About Publications Outreach

About

Research Focus:

I’m a Researcher based in Mara Martin-Alonso’s team at CEMIR, within the Department of Clinical and Molecular Medicine (IKOM) at NTNU.

Our main scientific goal is to understand how diseases in mucosal surfaces such as the gut are started and develop in time, including processes such as intestinal repair and tumorigenesis.

About me:

I have a Bachelor of Science with Honours degree (First Class; 2013) and PhD (Biochemistry; 2018) from the University of Otago, based in my home country New Zealand.

My PhD research project focussed on epithelial cancers arising from loss of the cell-to-cell adhesion protein E-cadherin (CDH1). Dysfunctional CDH1 underpins cancers such as diffuse gastric cancer and lobular breast cancer. This project involved testing novel drug combinations in vitro for potential therapeutic utility in these cancer subtypes. 

In 2019, I moved to Lund University, Sweden, to undertake a postdoctoral project researching novel molecular compounds for therapeutic use in respiratory diseases. This project involved an extensive use of in vivo mouse models of acute lung injury and pulmonary fibrosis to evaluate the compounds' effects.

I moved to Trondheim in 2021 to undertake a postdoctoral project investigating acquired chemotherapy resistance in ovarian cancer. This involved the use of freshly resected patient samples, primary cell co-cultures, and 3D culturing methods to study cell-cell and cell-ECM crosstalk in the tumour microenvironment.

In 2023, I joined Mara’s team as a Researcher to investigate the interplay between stem cells and neighbouring stroma in intestinal diseases such as colorectal cancer. Here, the use of murine models, ex vivo organoids, and confocal microscopy are central to our project.

Publications

  • LSD1 drives intestinal epithelial maturation and controls small intestinal immune cell composition independent of microbiota in a murine model. Diez-Sanchez, A., Lindholm, H., Vornewald, P., Ostrop, J., Yao, R., Single, A., Marstad, A., Parmar, N., Shaw, T., Martin-Alonso, M., and Oudhoff, M. Nature Communications, 15, 3412 (2024).
  •  Small-molecule-mediated OGG1 inhibition attenuates pulmonary inflammation and lung fibrosis in a murine lung fibrosis model. Tanner, L., Single, A., Bhongir, R., Heusel, M., Mohanty, T., Karlsson, C., Pan, L., Clausson, C., Bergwik, J., Wang, K., Andersson, C., Oommen, R., Erjefält, J., Malmström, J., Wallner, O., Boldogh, I., Helleday, T., Kalderén, C., and Egesten, A. Nature Communications, 14, 643 (2023).
  • Zoledronic acid targeting of the mevalonate pathway causes reduced cell recruitment and attenuates pulmonary fibrosis. Tanner, L., Bergwik, J., Single, A., Bhongir, R., Erjefält, J., and Egesten, A. Frontiers in Pharmacology, 13:899469 (2022).
  • Chemotherapy as a regulator of extracellular matrix-cell communication: Implications in therapy resistance. Gonzalez-Molina, J.*, Moyano-Galceran, L.*, Single, A.*, Gultekin, U., Alsalhi, S., and Lehti, K. Seminars in Cancer Biology, 86(3) (2022).
  • Citrullination of extracellular histone H3.1 reduces antibacterial activity and exacerbates its proteolytic degradation. Tanner, L., Bhongir, R., Karlsson, C., Le, S., Ljungberg, J., Andersson, P., Andersson, C., Malmström, J., Egesten, A., and Single, A. Journal of Cystic Fibrosis, 20(2) (2021).
  • Animal models reflecting chronic obstructive pulmonary disease and related respiratory disorders: translating pre-clinical data into clinical relevance. Tanner, L. and Single, A. Journal of Innate Immunity, 12(3) (2020).
  • Allosteric AKT inhibitors target synthetic lethal vulnerabilities in E-cadherin-deficient cells. Bougen-Zhukov, N., Nouri, Y., Godwin, T., Taylor, M., Hakkaart, C., Single, A., Brew, T., Permina, E., Chen, A., Black, M., and Guilford, P. Cancers, 11(9) (2019).
  • A high-throughput screen to identify novel synthetic lethal compounds for the treatment of E-cadherin-deficient cells. Beetham, H., Chen, A., Telford, B., Single, A., Jarman, K., Lackovic, K., Luxenburger, A., and Guilford, P. Scientific Reports, 9(1) (2019).
  • E-cadherin-deficient cells have synthetic lethal vulnerabilities in plasma membrane organisation, dynamics and function. Godwin, T., Kelly, S., Brew, T., Bougen-Zhukov, N., Single, A., Chen, A., Stylianou, C., Harris, L., Currie, S., Telford, B., Beetham, H., Evans, G., Black, M., and Guilford, P. Gastric Cancer, 22(2) (2019).
  • A comparison of real-time and endpoint cell viability assays for improved synthetic lethal drug validation. Single, A., Beetham, H., Telford, B., Guilford, P., and Chen, A. Journal of Biomolecular Screening, 20(10) (2015).
  • Synthetic lethal screens identify vulnerabilities in GPCR signalling and cytoskeletal organization in E-cadherin-deficient cells. Telford, B., Chen, A., Beetham, H., Frick, J., Brew, T., Gould, C., Single, A., Godwin, T., Simpson, K., and Guilford, P. Molecular Cancer Therapeutics, 14(5) (2015).
  • Chronological
  • By category
  • See all publications in Cristin

2024

  • Diez Sanchez, Alberto; Lindholm, Håvard Takle; Vornewald, Pia Magdalena; Ostrop, Jenny; Yao, Rouan; Single, Andrew Bruce. (2024) LSD1 drives intestinal epithelial maturation and controls small intestinal immune cell composition independent of microbiota in a murine model. Nature Communications
    Academic article

2022

  • Gonzalez-Molina, Jordi; Moyano-Galceran, Lidia; Single, Andrew; Gultekin, Okan; Alsalhi, Shno; Lehti, Kaisa. (2022) Chemotherapy as a regulator of extracellular matrix-cell communication: Implications in therapy resistance. Seminars in Cancer Biology
    Academic literature review

Journal publications

  • Diez Sanchez, Alberto; Lindholm, Håvard Takle; Vornewald, Pia Magdalena; Ostrop, Jenny; Yao, Rouan; Single, Andrew Bruce. (2024) LSD1 drives intestinal epithelial maturation and controls small intestinal immune cell composition independent of microbiota in a murine model. Nature Communications
    Academic article
  • Gonzalez-Molina, Jordi; Moyano-Galceran, Lidia; Single, Andrew; Gultekin, Okan; Alsalhi, Shno; Lehti, Kaisa. (2022) Chemotherapy as a regulator of extracellular matrix-cell communication: Implications in therapy resistance. Seminars in Cancer Biology
    Academic literature review

Outreach

2024

  • Poster
    Single, Andrew Bruce; Diez Sanchez, Alberto; Vornewald, Pia Magdalena; De Penning Aguilar, Sofia; Lee, Lilith Sian Kaspersen; Martin Alonso, Mara. (2024) Tumour promoter or tumour suppressor? Location-dependent role of LSD1 governs intestinal tumorigenesis. Gordon Research Conference Gordon Research Conference: Epithelial Stem Cells and Niches , Barcelona, Spain 2024-08-11 - 2024-08-16

NTNU – Norwegian University of Science and Technology

  • For employees
  • |
  • For students
  • |
  • Intranet
  • |
  • Blackboard

Studies

  • Master's programmes in English
  • For exchange students
  • PhD opportunities
  • Courses
  • Career development
  • Continuing education
  • Application process

News

  • NTNU News
  • Vacancies

About NTNU

  • About the university
  • Libraries
  • NTNU's strategy
  • Research excellence
  • Strategic research areas
  • Organizational chart

Contact

  • Contact NTNU
  • Employees
  • Find experts
  • Press contacts
  • Researcher support
  • Maps

NTNU in three cities

  • NTNU in Gjøvik
  • NTNU in Trondheim
  • NTNU in Ålesund

About this website

  • Use of cookies
  • Accessibility statement
  • Privacy policy
  • Editorial responsibility
Facebook Instagram Linkedin Snapchat Tiktok Youtube
Sign In
NTNU logo